Effect of lubiprostone on CKD patients to protect renal function

Effect of lubiprostone on CKD patients to protect renal function - Double blind test of lubiprostone for CKD patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023850

Enrollment

140

Registered

2017-01-23

Start date

2016-08-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease

Interventions

placebo, lubiprostone 8 mcg/day, lubiprostone 16 mcg/day lubiprostone 8 mcg/day lubiprostone 16 mcg/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patient with eFGR between 25-45 mL/min/1.73m2 for 3month

Exclusion criteria

Exclusion criteria: 1, inflammmatry diseases 2, oral absorbent 3, PSL more 5mg , immunosuppressant 4, oral absorbent 5, ARF 6, Drug-induced renal failure 7, renal transplant 8, RRT 9, gut obstruction 10, sensitive for lubiprostone 11, symptomatic constipation 12, diarrea 13, gut diesases 14, abdominal operation within 6 mo 15, HbA1c>9% 16, BP > 160/90 17, serious heart, liver, kidney, lung, CNS diseases 18, malignancy 19, unable for contraception 20, other clinical study enrollment within 3mo 21, exacerbation of lab data during screening 22, Can not follow instruction 23, Inadequate for trial

Design outcomes

Primary

Measure	Time frame
Change of concentration of serum indoxyl sulfate before and after administration	—

Countries

Japan

Contacts

Public ContactTakaaki ABE

Tohoku University Hospital Clincal Research Center

jinushi@hosp.tohoku.ac.jp022-717-7774

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026